Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN.

Eur Urol. 2020 Apr;77(4):436-438. doi: 10.1016/j.eururo.2019.12.014. Epub 2020 Feb 7. No abstract available.

PMID:
32037144
2.

Erdafitinib in Urothelial Carcinoma.

Sonpavde G, Sjödahl G.

N Engl J Med. 2019 Oct 17;381(16):1594. doi: 10.1056/NEJMc1911187. No abstract available.

PMID:
31618552
3.

Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.

Sjödahl G, Eriksson P, Patschan O, Marzouka NA, Jakobsson L, Bernardo C, Lövgren K, Chebil G, Zwarthoff E, Liedberg F, Höglund M.

Int J Cancer. 2020 May 1;146(9):2636-2647. doi: 10.1002/ijc.32737. Epub 2019 Nov 14.

4.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26.

5.

Molecular pathology of the luminal class of urothelial tumors.

Bernardo C, Eriksson P, Marzouka NA, Liedberg F, Sjödahl G, Höglund M.

J Pathol. 2019 Nov;249(3):308-318. doi: 10.1002/path.5318. Epub 2019 Aug 27.

6.

Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival.

Kollberg P, Chebil G, Eriksson P, Sjödahl G, Liedberg F.

Urol Oncol. 2019 Oct;37(10):791-799. doi: 10.1016/j.urolonc.2019.04.010. Epub 2019 May 2.

PMID:
31056435
7.

Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.

Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM.

J Pathol. 2019 Apr;247(5):563-573. doi: 10.1002/path.5230. Epub 2019 Feb 20. Review.

PMID:
30604486
8.
9.

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.

Warrick JI, Sjödahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ.

Eur Urol. 2019 Jan;75(1):18-22. doi: 10.1016/j.eururo.2018.09.003. Epub 2018 Sep 25.

PMID:
30266310
11.

Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays.

Jakobsson L, Chebil G, Marzouka NA, Liedberg F, Sjödahl G.

Bladder Cancer. 2018 Jul 30;4(3):327-337. doi: 10.3233/BLC-180176.

12.

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, Sjödahl G, Salmond JM, Sansom OJ, Iwata T.

J Pathol. 2018 Nov;246(3):331-343. doi: 10.1002/path.5143. Epub 2018 Sep 19.

13.

Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.

Sjödahl G, Eriksson P, Lövgren K, Marzouka NA, Bernardo C, Nordentoft I, Dyrskjøt L, Liedberg F, Höglund M.

Mod Pathol. 2018 Dec;31(12):1869-1881. doi: 10.1038/s41379-018-0096-5. Epub 2018 Jul 2.

14.

Molecular subtype classification of urothelial carcinoma in Lynch syndrome.

Therkildsen C, Eriksson P, Höglund M, Jönsson M, Sjödahl G, Nilbert M, Liedberg F.

Mol Oncol. 2018 Aug;12(8):1286-1295. doi: 10.1002/1878-0261.12325. Epub 2018 Jun 19.

15.

A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.

Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M.

Sci Rep. 2018 Feb 27;8(1):3737. doi: 10.1038/s41598-018-22126-x.

16.

Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.

Sjödahl G.

Methods Mol Biol. 2018;1655:53-64. doi: 10.1007/978-1-4939-7234-0_5.

PMID:
28889377
17.

Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.

Abrahamsson J, Aaltonen K, Engilbertsson H, Liedberg F, Patschan O, Rydén L, Sjödahl G, Gudjonsson S.

Urol Oncol. 2017 Oct;35(10):606.e9-606.e16. doi: 10.1016/j.urolonc.2017.05.021. Epub 2017 Jul 1.

PMID:
28676151
19.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
20.

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.

Eriksson P, Sjödahl G, Chebil G, Liedberg F, Höglund M.

Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.

21.

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.

Sjödahl G, Eriksson P, Liedberg F, Höglund M.

J Pathol. 2017 May;242(1):113-125. doi: 10.1002/path.4886. Epub 2017 Mar 28.

22.

Long-term functional outcomes after radical cystectomy with ileal bladder substitute: does the definition of continence matter?

Liedberg F, Ahlgren G, Baseckas G, Gudjonsson S, Håkansson U, Lindquist S, Löfgren A, Patschan O, Siller C, Sjödahl G.

Scand J Urol. 2017 Feb;51(1):44-49. doi: 10.1080/21681805.2016.1249943. Epub 2016 Nov 11.

PMID:
27834115
23.

On Molecular Classification of Bladder Cancer: Out of One, Many.

Aine M, Eriksson P, Liedberg F, Höglund M, Sjödahl G.

Eur Urol. 2015 Dec;68(6):921-3. doi: 10.1016/j.eururo.2015.07.021. Epub 2015 Jul 26.

PMID:
26215606
24.

Biological determinants of bladder cancer gene expression subtypes.

Aine M, Eriksson P, Liedberg F, Sjödahl G, Höglund M.

Sci Rep. 2015 Jun 8;5:10957. doi: 10.1038/srep10957.

25.

Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.

Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G, Höglund M.

BMC Med Genomics. 2015 May 26;8:25. doi: 10.1186/s12920-015-0101-5.

26.

Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma.

Aine M, Sjödahl G, Eriksson P, Veerla S, Lindgren D, Ringnér M, Höglund M.

Genome Med. 2015 Mar 10;7(1):23. doi: 10.1186/s13073-015-0144-4. eCollection 2015.

27.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486
28.

Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10.

Aine M, Liedberg F, Sjödahl G, Höglund M.

Eur Urol. 2015 Apr;67(4):e73-5. doi: 10.1016/j.eururo.2014.08.063. Epub 2014 Sep 4. No abstract available.

PMID:
25194907
29.

Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.

Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Månsson W, Fernö M, Leandersson K, Lindgren D, Liedberg F, Höglund M.

Urol Oncol. 2014 Aug;32(6):791-7. doi: 10.1016/j.urolonc.2014.02.007. Epub 2014 Apr 29.

30.

Toward a molecular pathologic classification of urothelial carcinoma.

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, Fernö M, Liedberg F, Höglund M.

Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.

31.

Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.

Eriksson P, Aine M, Sjödahl G, Staaf J, Lindgren D, Höglund M.

PLoS One. 2013 Jun 18;8(6):e67222. doi: 10.1371/journal.pone.0067222. Print 2013.

32.

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status.

Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, Chebil G, Lövgren K, Fernö M, Månsson W, Liedberg F, Ringnér M, Lindgren D, Höglund M.

Epigenetics. 2012 Aug;7(8):858-67. doi: 10.4161/epi.20837. Epub 2012 Jun 18.

33.

The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading.

Liedberg F, Lauss M, Patschan O, Aine M, Chebil G, Cwikiel M, Engilbertsson H, Gudjonsson S, Kollberg P, Sjödahl G, Månsson W, Lindgren D, Höglund M; Lund Bladder Cancer Group.

Eur Urol. 2012 Oct;62(4):620-3. Epub 2012 Jun 5. No abstract available.

PMID:
22698575
34.

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson W, Fernö M, Höglund M.

PLoS One. 2012;7(6):e38863. doi: 10.1371/journal.pone.0038863. Epub 2012 Jun 7.

35.

A molecular taxonomy for urothelial carcinoma.

Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M.

Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2.

36.

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Sjödahl G, Lauss M, Gudjonsson S, Liedberg F, Halldén C, Chebil G, Månsson W, Höglund M, Lindgren D.

PLoS One. 2011 Apr 14;6(4):e18583. doi: 10.1371/journal.pone.0018583.

37.

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, Veerla S, Ryden T, Månsson W, Liedberg F, Höglund M.

Cancer Res. 2010 May 1;70(9):3463-72. doi: 10.1158/0008-5472.CAN-09-4213. Epub 2010 Apr 20.

Supplemental Content

Loading ...
Support Center